Souhaitez-vous accéder aux communiqués récents ?

Konzernverkäufe stiegen um 6%1 zu konstanten Wechselkursen (CER; 7% in CHF) dank hoher Nachfrage nach innovativen Medikamenten und diagnostischen Lösungen.Verkäufe der Division Pharma wuchsen um 8%...

Group sales grew by 6%1 at constant exchange rates (CER; 7% in CHF), driven by high demand for newer medicines and diagnostic solutions.Pharmaceuticals Division sales rose by 8% (9% in CHF) on...

Stock Exchange Release  24th of April 2025 at 8 am (CET +1)  Sp Mortgage Bank Plc & Savings Banks Group: Half-Year Reports for 1st of January–30th of June 2024 will be published on 13th of August...

Stock Exchange Release  24th of April 2025 at 8 am (CET +1)  Central Bank of Savings Banks Finland Plc & Savings Banks Group: Half year Reports for 1st of January–30th of June 2025 will be...

The council of Nordecon AS approved on 23 April 2025 the consolidated audited annual report and profit allocation proposal for the year 2024. The council decided to present the annual report and...

Press release – No. 6 / 2025 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes The Phase 2b...

The management board of Nordecon AS (the “Company”) (registry code 10099962, address Toompuiestee 35, 10149 Tallinn) hereby calls an annual general meeting of shareholders, which shall be held on 21...

PR No: C3332C  STMicroelectronics Reports 2025 First Quarter Financial Results Q1 net revenues $2.52 billion; gross margin 33.4%; operating income $3 million; net income $56 millionBusiness outlook...

(2025-04-24) Kitron today reported first-quarter results characterised by continued momentum in the Defence & Aerospace market sector and a growing order backlog. Kitron's revenue for the first...

[Ad hoc announcement pursuant to Art. 53 LR] This press release is also available in Français (pdf) and Deutsch (pdf) Follow today's event live10:30 CEST Investor call audio webcastFull details on...